Maman Biomedical is developing a needle-free drug delivery platform designed to improve the experience of patients undergoing fertility treatments. The company highlights the challenges associated with IVF protocols, including multiple daily self-administered injections, high hormone exposure, rigid treatment schedules, and the psychological burden caused by needle anxiety. According to the presentation, these factors can negatively affect patient quality of life and treatment adherence.
The company’s initial product, Maman Port, is a hollow microneedle array device intended to replace conventional injections without requiring changes to existing fertility drugs. The device is positioned as a needle-free alternative that aims to reduce pain, eliminate blood exposure and sharps handling, and simplify treatment administration. The longer-term product roadmap includes Maman Sense, a hormone-monitoring platform, and Maman Patch, a sustained-release drug delivery system designed to reduce dosing frequency and improve hormonal control.
Maman Biomedical is targeting the fertility market as its initial commercial entry point. The presentation estimates a global IVF market of approximately $10 billion, with a potential needle-free IVF segment valued at around $1 billion. The company also outlines opportunities to expand into broader hormonal drug delivery applications, including growth hormone therapy, hormone replacement therapy, testosterone treatment, diabetes and obesity therapies, and contraceptives, representing a substantially larger addressable market.
The proposed business model involves supplying devices to fertility clinics and pharmacies, which would then distribute them to patients as part of fertility treatment protocols. The company reports letters of intent and expressions of interest from fertility clinics in North America and describes a commercialization strategy based on clinic adoption, pharmacy distribution, and recurring device sales. The roadmap anticipates regulatory milestones, clinical validation, and eventual market entry through a staged development process.
The company reports progress including a provisional patent application, clinic partnerships, surveyed users, industry recognition, and over CAD $700,000 raised to date. The team combines expertise in materials science, reproductive biology, medical devices, commercialization, governance, and fertility operations. Maman Biomedical is currently raising CAD $500,000 to support its first human clinical trial, regulatory preparation, manufacturing readiness, and product development activities, while positioning for a larger future financing round.